Opioid Use Disorder Medications

Opioid use disorder has the strongest pharmacotherapy options of any substance category. The three FDA-approved medications (methadone, buprenorphine, and naltrexone) differ substantially in their mechanism, access, and philosophy of treatment.

Methadone (Dolophine, Methadose)

Original developer: Synthesized in 1937 by German chemists Max Bockmühl and Gustav Ehrhart at IG Farben, the German chemical conglomerate. After World War II, the US company Eli Lilly acquired the rights and introduced it commercially in 1947 under the brand name Dolophine.
FDA approval as analgesic: 1947. Use for addiction treatment began in the 1960s through the pioneering work of Drs. Vincent Dole and Marie Nyswander at Rockefeller University.
How it works: A full opioid agonist that occupies the same receptors as heroin or prescription opioids, but with a much longer half-life. A single dose prevents withdrawal and reduces cravings for 24-36 hours without producing the euphoric high of short-acting opioids.

Methadone treatment is the oldest medication-assisted approach to addiction, dating back to the 1960s when Dole and Nyswander demonstrated that stabilized patients on methadone could hold jobs, rebuild family relationships, and stop using heroin. Their work fundamentally changed how medicine viewed addiction: not as a moral failing, but as a chronic condition that could be managed pharmacologically, like diabetes.

Today, methadone is dispensed only through federally certified opioid treatment programs (OTPs), where patients visit daily for supervised dosing. This structure, the daily clinic visits, is both the medication's greatest strength and its greatest weakness. It provides accountability and structure that some patients need, but it also creates significant barriers: travel time, stigma, and limits on employment and travel. Despite these barriers, methadone remains one of the most studied and effective treatments for opioid use disorder.

Buprenorphine (Subutex, Suboxone, Sublocade, Brixadi)

Original developer: First synthesized in 1966 by chemist John Lewis at Reckitt & Colman, a British pharmaceutical company (later merged into Reckitt Benckiser). In 2014, the buprenorphine business was spun off into a separate company called Indivior, which remains the primary manufacturer.
FDA approval: 2002 (Subutex and Suboxone). Sublocade (monthly injectable by Indivior) approved 2017. Brixadi (weekly/monthly injectable by Braeburn Inc.) approved 2023.
How it works: A partial opioid agonist. It activates opioid receptors enough to prevent withdrawal and cravings, but not enough to produce the full euphoric effect of heroin or oxycodone. It also has a "ceiling effect": beyond a certain dose, taking more does not increase the effect, which greatly reduces the risk of fatal overdose compared to full agonists like methadone.

Buprenorphine's development was shaped by a specific problem: methadone worked, but its restriction to specialized clinics created an access bottleneck. In 1993, the National Institute on Drug Abuse (NIDA) approached Reckitt about developing a medication that could be prescribed in a regular doctor's office. The result was Suboxone, buprenorphine combined with naloxone. The naloxone is inactive when taken as prescribed (under the tongue) but causes immediate withdrawal if someone tries to inject the tablet, discouraging misuse.

The Drug Addiction Treatment Act of 2000 (DATA 2000) allowed qualified physicians to prescribe buprenorphine from their offices, dramatically expanding access. This was a watershed moment in addiction medicine: for the first time, people with opioid use disorder could receive medication from their regular doctor rather than a specialized clinic.

The injectable forms, Sublocade (monthly) and Brixadi (weekly or monthly), represent the next generation. They eliminate the daily decision of whether to take a pill or film strips. A single injection provides a steady level of medication for weeks, removing both the burden of daily dosing and the temptation to sell or divert the medication.

Nicotine / Tobacco Use Disorder Medications

Smoking kills more people than alcohol and all other drugs combined. The medications available to treat nicotine addiction reflect the scale of this public health problem: there are more FDA-approved options for nicotine dependence than for any other substance.

Nicotine Replacement Therapy (NRT)

Original developer: The first nicotine gum (Nicorette) was developed by Swedish researcher Ove Fernö in the 1970s. Fernö, working for the Swedish pharmaceutical company Pharmacia (later Pharmacia & Upjohn, now part of Pfizer), was inspired by his observation that submarine crews and flight personnel, unable to smoke for extended periods, would switch to smokeless tobacco to manage cravings. He reasoned that a pharmaceutical nicotine product could do the same thing more safely.
FDA approval: Nicotine gum approved 1984. Patches followed in the 1990s. Today NRT is available as gum, lozenge, patch, inhaler, and nasal spray (all OTC except inhaler and spray).
How it works: Delivers a controlled, therapeutic dose of nicotine without the toxins and carcinogens in tobacco smoke. By providing a steady, low-level nicotine supply, NRT reduces both cravings and withdrawal symptoms while the person breaks the behavioral habits associated with smoking.

Nicotine replacement is the most accessible form of addiction medication. Because most forms are available over the counter, no prescription is needed. The patch provides a steady baseline dose throughout the day, while the gum, lozenge, inhaler, or spray can be used for breakthrough cravings.

The key to NRT effectiveness: using enough for long enough. Many people use too little (a single patch when heavier smokers may need higher doses) or stop too soon. Guidelines typically recommend 8-12 weeks of use, with gradual tapering, though some people benefit from longer courses.

Bupropion (Zyban / Wellbutrin)

Original developer: Invented in 1969 by chemist Nariman Mehta at Burroughs Wellcome (a British pharmaceutical company founded in 1880, later merged into Glaxo Wellcome and eventually GlaxoSmithKline).
FDA approval: First approved as an antidepressant (Wellbutrin) in 1985. Approved for smoking cessation (Zyban) in 1997.
How it works: A norepinephrine-dopamine reuptake inhibitor (NDRI). It increases the availability of dopamine and norepinephrine in the brain, the same neurotransmitter systems affected by nicotine. This helps reduce cravings and withdrawal symptoms.

Bupropion's journey from antidepressant to smoking cessation aid is a good example of how medications are sometimes repurposed. Clinicians noticed that depressed patients taking Wellbutrin spontaneously reported losing interest in smoking. Follow-up studies confirmed the effect: bupropion roughly doubles a person's odds of quitting successfully compared to placebo, even in people without depression.

An important advantage: bupropion can be started while the person is still smoking. The typical protocol is to begin taking it one to two weeks before the target quit date, allowing the medication to build up in the system. This stands in contrast to varenicline, which also allows pre-quit dosing, and NRT, which is typically started on the quit date.

Varenicline (Chantix / Champix)

Original developer: Pfizer, the American pharmaceutical giant. Development began in the 1990s based on research into cytisine, a plant alkaloid used for smoking cessation in Eastern Europe since the 1960s.
FDA approval: May 2006.
How it works: A partial agonist at nicotinic acetylcholine receptors, the same receptors that nicotine binds to. By occupying these receptors, varenicline does two things at once: it stimulates them enough to reduce cravings and withdrawal (agonism), and it blocks nicotine from binding if the person smokes, preventing the rewarding effect (antagonism).

Varenicline is often described as the most effective single medication for smoking cessation. The large EAGLES trial (2016, over 8,000 participants) directly compared varenicline, bupropion, nicotine patch, and placebo: varenicline produced the highest quit rates without increasing neuropsychiatric side effects, even in people with mental health conditions.

The medication's mechanism is elegant: it partially activates the same receptor that nicotine fully activates, so the brain gets enough stimulation to avoid withdrawal, but smoking provides no additional reward. This dual action of relief from withdrawal plus blockade of the drug's effect is a pharmacological model that researchers continue to study for other addictions.

Varenicline is typically taken for 12 weeks, though some people benefit from longer courses. Common side effects include nausea (which often improves over time) and vivid dreams. The medication was temporarily unavailable in some markets between 2021 and 2022 due to a manufacturing recall related to nitrosamine impurities, but reformulated versions have since returned.

Discontinued and Historical Medications

Not every medication that reaches the market stays there. Several have been withdrawn due to safety concerns, replaced by better alternatives, or simply faded from use.

LAAM / Orlaam (Levacetylmethadol)

Original developer: Roxane Laboratories (US).
FDA approval: 1993. Removed from European market 2001. Discontinued in the United States 2003.
Why it was discontinued: Severe cardiac side effects, specifically ventricular rhythm disorders (torsades de pointes) that could cause sudden death.

LAAM was a longer-acting alternative to methadone: patients only needed to visit a clinic two or three times per week instead of every day. This was a significant advantage for stable patients trying to maintain employment and normal routines.

In 2001, the European Medicines Agency suspended LAAM's marketing authorization after multiple reports of life-threatening heart rhythm abnormalities. The FDA followed with a black box warning and mandated that all patients receiving LAAM undergo regular ECG monitoring. Most clinics, lacking the resources for routine cardiac screening, simply stopped prescribing it. Roxane Laboratories formally discontinued Orlaam in the US in 2003.

The lesson of LAAM is instructive: its core idea, less frequent dosing, was sound. The problem was the specific molecule and its cardiac toxicity, not the concept. That same idea eventually resurfaced in Sublocade and Brixadi, the monthly injectable forms of buprenorphine, which achieve the goal of infrequent dosing through a completely different (and safer) delivery mechanism.

Ibogaine: Experimental, Never FDA-Approved

Origin: A psychoactive alkaloid derived from the root bark of Tabernanthe iboga, a shrub native to Central West Africa, where it has been used for centuries in spiritual ceremonies by the Bwiti religion in Gabon.
Status: Never approved as a medication in the United States or Europe. Used in unregulated clinics in Mexico, Costa Rica, and other countries.
Why it is not approved: Significant safety concerns, including a risk of fatal cardiac arrhythmias. Several deaths have been reported at ibogaine treatment centers.

Ibogaine occupies an unusual position: widely discussed in addiction communities, extensively covered by media, yet lacking the controlled clinical trials that would be required for regulatory approval. Anecdotal reports describe dramatic reductions in opioid withdrawal and cravings after a single dose, sometimes lasting for weeks or months.

The mechanism is not fully understood, but animal studies suggest ibogaine may promote neuroplasticity, the brain's ability to rewire itself, and may interact with multiple neurotransmitter systems including serotonin, dopamine, and opioid receptors. In recent years, researchers have developed a synthetic derivative called 18-MC (18-methoxycoronaridine) that aims to reproduce ibogaine's anti-addictive effects without the cardiac toxicity. 18-MC is currently in early-stage clinical research but has not reached the point of FDA submission.

The gap between anecdotal enthusiasm and clinical evidence is wide. Ibogaine's story highlights a recurring theme in addiction medicine: promising ideas that need rigorous safety testing before they can become treatments.

Challenges in Addiction Pharmacotherapy

Despite having several effective medications, the gap between what works and what is actually used is enormous. Only a small fraction of people with substance use disorders receive medication-assisted treatment.

• ⚠ Stigma: A persistent belief, even among some healthcare providers, that using medication to treat addiction is "replacing one drug with another." This is like saying insulin "replaces" food for a diabetic. The medications treat the underlying neurobiology of the condition.
• ⚠ Access: Methadone requires daily clinic visits. Buprenorphine requires a specially waivered prescriber (in the US). Vivitrol requires monthly injections by a healthcare professional. These structural barriers keep effective medications out of reach for many who need them.
• ⚠ No medications for stimulant or cannabis disorders: Cocaine and methamphetamine addiction have no FDA-approved pharmacotherapy, despite decades of research. The same is true for cannabis use disorder. This is one of the most urgent gaps in addiction medicine.
• ⚠ Cost: Newer medications like Vivitrol and Sublocade are expensive. Insurance coverage varies widely, and the uninsured are often unable to access the most effective options.
• ⚠ Limited industry investment: Developing new addiction medications is expensive and the market is perceived as small compared to conditions like diabetes or hypertension. Few pharmaceutical companies prioritize addiction R&D.

Final Thought

The medications described in this guide are not cures. Addiction is a chronic condition, and like other chronic conditions, treatment often involves long-term management rather than a single curative intervention. But the evidence is clear: pharmacotherapy, combined with counseling and social support, significantly improves outcomes. It reduces overdose deaths. It helps people stay in treatment. It gives them the stability they need to rebuild their lives.

If any of the patterns or habits discussed here resonate with you, the most useful step you can take is to reflect on your own situation in a structured way. Take our Addiction Check to get a clearer picture of where you stand. No registration is required. Immediate results.

If you want to understand how these conditions are screened, read about common addiction screening tests. And when a setback happens, remember that recovery is not a straight line.